The Targeted SMAC Mimetic SW IV-134 is a strong enhancer of standard chemotherapy in pancreatic cancer
详细信息 查看全文
- 作者：Yassar M. Hashim ; Suwanna Vangveravong…
- 关键词：Sigma ; 2 receptors ; Sigma ; 2/SMAC drug conjugate ; Gemcitabine ; Combination therapy ; Pancreatic cancer
- 刊名：Journal of Experimental & Clinical Cancer Research
- 出版年：2017
- 出版时间：December 2017
- 年：2017
- 卷：36
- 期：1
- 全文大小：1762KB
- 刊物主题：Oncology; Cancer Research; Immunology; Apoptosis;
- 出版者：BioMed Central
- ISSN：1756-9966
- 卷排序：36
文摘
BackgroundPancreatic cancer is a lethal malignancy that frequently acquires resistance to conventional chemotherapies often associated with overexpression of inhibitors of apoptosis proteins (IAPs). We have recently described a novel means to deliver second mitochondria-derived activator of caspases (SMAC) mimetics selectively to cancer cells employing the sigma-2 ligand/receptor interaction. The intrinsic death pathway agonist SMAC offers an excellent opportunity to counteract the anti-apoptotic activity of IAPs. SMAC mimetics have been used to sensitize several cancer types to chemotherapeutic agents but cancer-selective delivery and appropriate cellular localization have not yet been considered. In our current study, we tested the ability of the sigma-2/SMAC drug conjugate SW IV-134 to sensitize pancreatic cancer cells to gemcitabine.